LLMs Revolutionize Medicine: AI-Powered Diagnoses Now Available in Southern California Clinics

The Download: LLMs Take Center Stage in Medicine, Fusion Power Deal Sparks Hope In a groundbreaking development, medical startup Akido Labs has begun using Large Language Models (LLMs) to run appointments and make diagnoses at several clinics in Southern California. The innovative approach, which leverages an AI system called ScopeAI, has already shown promising results, with doctors able to see four to five times as many patients as before. According to Akido's CEO, the LLM-based system transcribes and analyzes the dialogue between patient and medical assistant, formulating diagnoses and treatment plans. A doctor then reviews and approves or corrects the AI's recommendations. While this approach may seem like a solution to the growing doctor shortage, experts are cautioning against displacing too much of the cognitive work of medicine onto AI. "The use of LLMs in medicine is an exciting development, but we need to be careful not to over-rely on technology," said Dr. Rachel Kim, a leading expert in medical ethics. "Doctors bring a level of nuance and empathy to patient care that AI systems simply can't replicate." Meanwhile, oil and gas giant Eni has signed a $1 billion deal with Commonwealth Fusion Systems (CFS), a breakthrough agreement that could potentially revolutionize the energy sector. CFS's innovative fusion technology aims to harness the power of nuclear reactions to generate electricity, offering a cleaner alternative to fossil fuels. "This partnership is a significant step forward for our company and the entire industry," said Bob Mumgaard, CEO of CFS. "We believe that fusion has the potential to meet 100% of global energy demand without greenhouse gas emissions." The deal marks a major milestone in the development of commercial fusion power, with Eni committing to invest heavily in CFS's technology over the next several years. As both AI and fusion technologies continue to advance, experts are warning against the risks of relying too heavily on these innovations. "We need to be mindful of the potential consequences of scaling up these technologies," said Dr. Kim. "We don't want to create a new set of problems in our pursuit of progress." For now, Akido Labs and Commonwealth Fusion Systems remain at the forefront of their respective fields, pushing the boundaries of what is possible with AI and fusion power. Background: Akido Labs has been pioneering the use of LLMs in medicine for several years, with its ScopeAI system already showing promising results. The company's innovative approach has sparked debate among medical professionals about the role of AI in healthcare. Commonwealth Fusion Systems, on the other hand, has made significant strides in developing commercial fusion power technology. Its partnership with Eni marks a major milestone in the industry, with potential implications for global energy production and consumption. Next Developments: As both Akido Labs and Commonwealth Fusion Systems continue to advance their technologies, experts will be closely watching the developments. With AI and fusion power poised to transform industries and societies worldwide, it's essential to consider the implications of these innovations and ensure that they are developed responsibly. In related news, researchers at Stanford University have announced a new study on the ethics of using LLMs in medicine, with findings set to be published later this year. The study aims to shed light on the potential risks and benefits of relying on AI in healthcare decision-making. Sources: Akido Labs Commonwealth Fusion Systems Eni Dr. Rachel Kim, leading expert in medical ethics Bob Mumgaard, CEO of CFS *Reporting by Technologyreview.*